Short Interest in Genenta Science S.p.A. (NASDAQ:GNTA) Expands By 30.8%

Genenta Science S.p.A. (NASDAQ:GNTA) has seen a significant increase in short interest throughout January. As of January 31st, short interest reached a total of 3,400 shares, marking a 30.8% rise from the 2,600 shares reported on January 15th. With an average daily trading volume of 10,600 shares, the current days-to-cover ratio stands at 0.3 days.

Institutional Investors Take Notice of Genenta Science

In recent developments, an institutional investor took a new position in Genenta Science stock. Allianz SE purchased 103,250 shares during the fourth quarter, valued at around $444,000, as per its latest 13F filing with the Securities and Exchange Commission. Following this acquisition, Allianz SE held about 0.56% of Genenta Science shares at the conclusion of the most recent reporting period. Overall, hedge funds and other institutional investors collectively own 15.13% of the firm's stock.

Genenta Science Stock Performance

On the trading day of Friday, Genenta Science shares rose by $0.55 to reach a price of $4.37. A total of 6,022 shares were traded that day, compared to an average volume of 10,297 shares. The company's fifty-day moving average stood at $4.46, while the two-hundred-day moving average was at $4.59. Over the past year, Genenta Science experienced a low of $2.20 and a high of $7.28.

About Genenta Science

Genenta Science S.p.A. is a biotechnology company in the clinical stage, primarily focused on developing hematopoietic stem cell gene therapies aimed at treating solid tumors in Italy. Its lead product candidate is Temferon, currently in Phase 1/2a clinical trials, designed to address glioblastoma multiforme in patients with an unmethylated MGMT gene promoter.

Genenta, Investors, Stocks